HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830
Question
HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830
Direct answer
Clinical advancement of dual-targeted oncology conjugates creates milestone validation for small-molecule oncology pipelines. — bullish pressure on HCM via clinical milestone progression in proprietary oncology pipeline.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-28
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830”, revision 1, evidence through 2026-09-28. https://marketontology.com/catalysts/2026-09-28/hutchmed-doses-first-patient-in-phase-ia-trial-of-kras-egfr-conjugate-hmpl-a830-0becd9
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| HCM | ▲Bull | 1–3 months | clinical milestone progression in proprietary oncology pipeline | 68 |
HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830
Clinical advancement of dual-targeted oncology conjugates creates milestone validation for small-molecule oncology pipelines. — bullish pressure on HCM via clinical milestone progression in proprietary oncology pipeline.
First patient dosed in Phase Ia clinical trial for HMPL-A830
- SourceFirst patient dosed in Phase Ia clinical trial for HMPL-A830
- TransmissionClinical advancement of dual-targeted oncology conjugates creates milestone validation for small-molecule oncology pipelines.
- SummaryHUTCHMED begins Phase Ia clinical dosing for solid tumor candidate HMPL-A830. First-in-class construct pairs KRAS inhibition directly with anti-EGFR antibody targeting. First patient was officially dosed on September 24, 2026.
- HCMDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- HCM closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- HCM price vs. pre-event level
- HCM volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| HCM | Bullishagreed | 14.13 2026-09-28 | +0.14% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors · GlobeNewswire Inc. · 2026-09-28
Related catalysts
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-28HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR ConjugateGSK HCM+0.14%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.